晚期肝癌多相脂质体介入化疗的疗效分析  

ADM LIPOSOME THERAPY IN THE TREATMENT OF FORTY FIVE PATIENTS WITH ADVANCED LIVER CANCER

作　　者：高普均[1] 马琳 徐昕[1] 

机构地区：[1]白求恩医科大学第一临床学院,吉林长春130021 [2]吉林省肿瘤医院,吉林长春130012

出　　处：《肿瘤研究与临床》2000年第6期405-406,共2页Cancer Research and Clinic

摘　　要：目的 :对比观察阿霉素 (ADM)多相脂质体与游离 ADM治疗晚期肝癌近期疗效及副作用。方法 :131例晚期肝癌患者 ,随机分成两组 ,A组为 ADM多相脂质体介入化疗组 (治疗组 ) ,B组为游离 ADM介入化疗组(对照组 )。结果 :平均生存期 1a生存率两组无明显差别 ,近期疗效 A组优于 B组 ,毒副作用 A组较 B组轻。结论 :两种治疗方法平均生存期无明显差异 ,ADM多相脂质体介入化疗可提高近期疗效 ,降低毒副作用 。Objective:To compare the survival rate and side effects of doxorubic in (ADM) liposome therapy and ADM therapy for liver cancer.Methods:87 patients with advanced liver cancer were divided into two groups:Group A was treated by ADM liposome chemotherapy and group B by ADM chemotherapy.Results:The mean survival and 1 year survival rates showed no obvious difference in both groups.However,patients in Group A showed better immediate curative effect and lower immediate side effects than Group B.Conclusion:ADM Liposome chemotherapy increase the immediate curative effects and decrease the general reactions.

关 键 词：脂质体 阿霉素 肝癌 

分 类 号：R735.7[医药卫生—肿瘤]